SEC Comment Letter 0000000000-23-012075 to BioXcel Therapeutics, Inc. (BTAI) (CIK 0001720893) (BTAI)
BioXcel Therapeutics, Inc. (BTAI) (CIK 0001720893)
Date: Nov. 3, 2023 · CIK: 0001720893 · Accession: 0000000000-23-012075
AI Filing Summary & Sentiment
File numbers found in text: 333-275261
Letter
United States securities and exchange commission logo November 3, 2023 Vimal Mehta, Ph.D. Chief Executive Officer BioXcel Therapeutics, Inc. 780 East Main Street Branford, CT 06405 Re:BioXcel Therapeutics, Inc. Registration Statement on Form S-3 Filed November 2, 2023 File No. 333-275261 Dear Vimal Mehta: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Keith L. Halverstam
Show Raw Text
United States securities and exchange commission logo
November 3, 2023
Vimal Mehta, Ph.D.
Chief Executive Officer
BioXcel Therapeutics, Inc.
780 East Main Street
Branford, CT 06405
Re:BioXcel Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 2, 2023
File No. 333-275261
Dear Vimal Mehta:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Keith L. Halverstam